Last reviewed · How we verify
Continuous OC (EE/DROS)
Continuous OC (EE/DROS) is an oral contraceptive containing ethinyl estradiol and drospirenone that prevents pregnancy through hormonal suppression of ovulation.
Continuous OC (EE/DROS) is an oral contraceptive containing ethinyl estradiol and drospirenone that prevents pregnancy through hormonal suppression of ovulation. Used for Contraception, Reduction of menstrual bleeding.
At a glance
| Generic name | Continuous OC (EE/DROS) |
|---|---|
| Also known as | Yaz |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | FDA-approved |
Mechanism of action
This combination oral contraceptive works by delivering a continuous dose of ethinyl estradiol (a synthetic estrogen) and drospirenone (a progestin with antimineralocorticoid activity) to suppress the luteinizing hormone surge required for ovulation. The continuous formulation eliminates the hormone-free interval found in traditional cyclic pills, reducing breakthrough bleeding and providing consistent contraceptive coverage throughout the cycle.
Approved indications
- Contraception
- Reduction of menstrual bleeding
Common side effects
- Breakthrough bleeding
- Nausea
- Headache
- Breast tenderness
- Mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Continuous OC (EE/DROS) CI brief — competitive landscape report
- Continuous OC (EE/DROS) updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI